Citations

Showing 10 of 108119 citations.

From Resistant Airway to Resistant Hypertension
Covassin, Naima , Somers, Virend K.

Mayo Clinic

Circulation | March 4, 2019 | Volume: 139 | Issue: 10 | Pages: 1285-1288

10.1161/circulationaha.118.038591 | PMID 30865474 Get It

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, Suzanne E. , Li, Yan , Todd, Kaitlin , Herries, Elizabeth, Henson, Rachel L. , Gray, Julia, Wang, Guoqiao , Graham, Danielle , Shaw, Leslie M. , Trojanowski, John Q. , Hassenstab, Jason , Benzinger, Tammie L.S. , Cruchaga, Carlos , Xiong, Chengjie , Chhatwal, Jasmeer P. , Noble, James M. , Ringman, John M. , Graff‐Radford, Neill R. , Ladenson, Jack H., Morris, John C. , Bateman, Randall J. , Fagan, Anne M. , Network, Dominantly Inherited Alzheimer, Fox, Nick C. , Cruchaga, Carlos , Bateman, Randall J , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , Holtzman, David M. , Xiong, Chengjie , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | March 4, 2019 | Volume: 15 | Issue: 5 | Pages: 655-665

10.1016/j.jalz.2018.12.019 | PMID 30846386 Get It

AbstractIntroductionFour less well‐studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late‐onset Alzheimer disease (AD): neurogranin, synaptosomal‐associated protein‐25 (SNAP‐25), visinin‐like protein 1 (VILIP‐1), and chitinase‐3‐like protein 1 (YKL‐40).MethodsCSF neurogranin, SNAP‐25, VILIP‐1, and YKL‐40 were measured in families carrying autosomal‐dominant AD mutations.ResultsThe four emerging CSF biomarkers were significantly elevated in the mutation carriers (n = 235) versus noncarriers (n = 145). CSF SNAP‐25, VILIP‐1, and YKL‐40 were altered very early in the AD time course, approximately 15–19 years before estimated symptom onset. All CSF biomarkers predicted important AD‐related outcomes including performance on a cognitive composite, brain amyloid burden as measured by amyloid positron emission tomography, and the estimated years from symptom onset.DiscussionEarly abnormalities in CSF tTau, pTau, SNAP‐25, VILIP‐1, and YKL‐40 suggest that synaptic damage, neuronal injury, and neuroinflammation begin shortly after the commencement of brain amyloid accumulation.
Clarifications Needed on Study of Association Between Physician Burnout and Patient Safety
Shanafelt, Tait D. , Dyrbye, Lotte N, Shanafelt, Tait D , Dyrbye, Liselotte N. , West, Colin P.

Mayo Clinic

JAMA Internal Medicine | March 4, 2019 | Volume: 179 | Issue: 4 | Pages: 593

10.1001/jamainternmed.2019.0149 | PMID 30830173 Get It

Dr Shahbudin H. Rahimtoola
Frye, Robert L.

Mayo Clinic

European Heart Journal | March 4, 2019 | Volume: 40 | Issue: 11 | Pages: 865-865

10.1093/eurheartj/ehz075 | PMID 30830951 Get It

An RCVS Spectrum Disorder? New Daily Persistent Headache Starting as a Single Thunderclap Headache (3 New Cases)
Jamali, Sheheryar A. , Rozen, Todd D.

Mayo Clinic

Headache: The Journal of Head and Face Pain | March 4, 2019 | Volume: 59 | Issue: 5 | Pages: 789-794

10.1111/head.13495 | PMID 30830966 Get It

Objective To describe 3 new cases of new daily persistent headache (NDPH) starting as a single thunderclap headache. Background NDPH is a form of chronic daily headache that is unique in its temporal profile of onset. Distinct subtypes of NDPH are being described with specific efficacious treatments. A single case of NDPH starting as a single thunderclap headache has been previously reported but no further cases have been documented in the literature. New cases need to be published to better define the syndrome. Methods To report a case series of patients diagnosed with this unique NDPH subtype at an academic headache center from 2016 to 2018. Results Three new cases of NDPH starting as a single thunderclap headache at onset were diagnosed. All patients were female with an average age of onset of 46 years. All presented with neurologic symptoms/stroke‐like spells at headache onset. No defined triggering events were noted in any of the patients. There is a possible seasonal predilection to develop the syndrome around the fall clock change to the winter solstice. Neuroimaging was normal in the case patients. All patients rapidly responded to nimodipine. The duration of headache prior to nimodipine therapy ranged from 3 months to 4 years. Conclusion This NDPH subtype appears to be rare. The key to diagnosis is asking about the temporal profile of the onset of the first ever NDPH headache. None of the case patients had been asked about the initial headache and its pattern of onset. Nimodipine seems to be very effective in treating this NDPH subtype. This syndrome is most likely precipitated by persistent or intermittent cerebral artery vasospasm. It is possibly a subform of the reversible cerebral vasoconstriction syndrome.
Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques
Matchett, William E. , Anguiano-Zarate, Stephanie S., Shelton, Kathryn A. , Nehete, Bharti P. , Yang, Guojun , Dorta‐Estremera, Stephanie , Barnette, Philip , Xiao, Peng , Villinger, François , Hessell, Ann J. , Haigwood, Nancy L. , Barry, Michael A. , Barry, Michael A , Nehete, Pramod N. , Byrareddy, Siddappa N. , Sastry, K. Jagannadha

Mayo Clinic

Journal of Virology | March 4, 2019 | Volume: 93 | Issue: 10 | Pages: No page available

10.1128/jvi.02016-18 | PMID 30842321 Get It

HIV-1 infections usually start at a mucosal surface after sexual contact. Creating a barrier of protection at these mucosal sites may be a good strategy for to protect against HIV-1 infections. While HIV-1 enters at mucosa, most vaccines are not delivered here. Most are instead injected into the muscle, a site well distant and functionally different than mucosal tissues. This study tested if delivering HIV vaccines at mucosa or in the muscle makes a difference in the quality, quantity, and location of immune responses against the virus. These data suggest that there are indeed advantages to educating the immune system at mucosal sites with an HIV-1 vaccine.
A partially corrected estimate of medicaid enrollment and uninsurance: Results from an imputational model developed off linked survey and administrative data
Klerman, Jacob Alex, Ziegenfuss, Jeanette, Lynch, Victoria , Greenberg, George D., Davern, Michael J.

Mayo Clinic

Journal of Economic and Social Measurement | March 4, 2019 | Volume: 34 | Issue: 4 | Pages: 219-240

10.3233/jem-2009-0324 Get It

To improve the utility of estimates of Medicaid enrollment and uninsurance from the Current Population Survey (CPS) we use linked data from the CPS and the Medicaid Statistical Information System (MSIS) to build a probabilistic imputation model that partially corrects the public use data files for systematic under-reporting of Medicaid. We estimate the probability that a CPS survey case was enrolled in Medicaid, conditional on whether or not in the CPS the individual responded that they had Medicaid. We use the imputed data to develop adjusted estimates of Medicaid enrollment and uninsurance by demographic characteristics. The net Medicaid enrollment total using our imputation model for CY 2006 and 2007 is 41.0, compared to 34.0 million using the standard CPS variables. The resulting net adjusted uninsurance estimate is 4.5% below the unadjusted estimate.
Epicardial Adipose Tissue and Renal Disease
Aeddula, Narothama Reddy , Cheungpasitporn, Wisit , Pathireddy, Samata, Cheungpasitporn, Wisit , Aeddula, Narothama Reddy , Thongprayoon, Charat

Mayo Clinic

Journal of Clinical Medicine | March 4, 2019 | Volume: 8 | Issue: 3 | Pages: 299

10.3390/jcm8030299 | PMID 30832377 Get It

Epicardial adipose tissue (EAT) is derived from splanchnic mesoderm, localized anatomically between the myocardium and pericardial visceral layer, and surrounds the coronary arteries. Being a metabolically active organ, EAT secretes numerous cytokines, which moderate cardiovascular morphology and function. Through its paracrine and vasocrine secretions, EAT may play a prominent role in modulating cardiac function. EAT protects the heart in normal physiological conditions by secreting a variety of adipokines with anti-atherosclerotic properties, and in contrast, secretes inflammatory molecules in pathologic conditions that may play a dynamic role in the pathogenesis of cardiovascular diseases by promoting atherosclerosis. Considerable research has been focused on comparing the anatomical and biochemical features of EAT in healthy people, and a variety of disease conditions such as cardiovascular diseases and renal diseases. The global cardiovascular morbidity and mortality in renal disease are high, and there is a paucity of concrete evidence and societal guidelines to detect early cardiovascular disease (CVD) in this group of patients. Here we performed a clinical review on the existing evidence and knowledge on EAT in patients with renal disease, to evaluate its application as a reliable, early, noninvasive biomarker and indicator for CVD, and to assess its significance in cardiovascular risk stratification.
Detection of Human Plasma Glucose Using a Self-Powered Glucose Biosensor
Kulkarni, Tanmay , Slaughter, Gymama E.

Mayo Clinic

Energies | March 4, 2019 | Volume: 12 | Issue: 5 | Pages: 825

10.3390/en12050825 Get It

This work presents the characterization of a self-powered glucose biosensor using individual sequential assays of human plasma glucose obtained from diabetic patients. The self-powered glucose biosensor is exploited to optimize the assay parameters for sensing plasma glucose levels. In particular, the biofuel cell component of the system at pH 7.4, 37 °C generates a power density directly proportional to plasma glucose and exhibited a maximum power density of 0.462 mW·cm−2 at a cell voltage of 0.213 V in 5 mM plasma glucose. Plasma glucose is further sensed by monitoring the charge/discharge frequency (Hz) of the integrated capacitor functioning as the transducer. With this method, the plasma glucose is quantitatively detected in 100 microliters of human plasma with unprecedented sensitivity, as high as 104.51 ± 0.7 Hz·mM−1·cm−2 and a detection limit of 2.31 ± 0.3 mM. The results suggest the possibility to sense human plasma glucose at clinically relevant concentrations without the use of an external power source.